Clinical Trial Update: Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study of XL147 (SAR245408) in combination with erlotinib in adults with solid tumors, including non-small cell lung cancer, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• XL147 (SAR245408)

Snippet

Sponsor: Sanofi | Conditions: Cancer, Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED